You are here:

midazolam (Buccolam oromucosal solution)


Following a full submission:
midazolam oromucosal solution (Buccolam®) is accepted for use within NHS Scotland.
Indication under review: Treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents (from 3 months to <18 years).
Midazolam given via the buccal route was considered at least non-inferior to rectally administered benzodiazepine in terminating acute prolonged seizures.
The economic case was demonstrated for midazolam oromucosal solution (Buccolam®) compared to rectal diazepam.

Drug Details

Drug Name: midazolam (Buccolam oromucosal solution)
SMC Drug ID: 757/12
Manufacturer: ViroPharma Ltd
Indication: For the treatment of prolonged , acute, convulsive seizures in infants, children and adolescents.
BNF Category:
Sub Category: 4.8 Antiepileptic drugs
Submission Type: Full submission
Status: Accepted
Date Advice Published: 13 February 2012